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,
and the Swiss HIV cohort studyAbstract
Plasma HIV viral load is related to declining CD4 lymphocytes. The extent to which CD8 cells, in addition to RNA viral load, predict the
depletion of CD4 cells is not well characterized so far. We examine if CD8 cell count is a prognostic factor for CD4 cell counts during
an HIV infection.
A longitudinal analysis is conducted using data from the Swiss HIV cohort study collected between January 2000 and October
2014. Linear mixed regression models were applied to observations fromHIV-1-infected treatment naive patients (NAIVE) and cART-
treated patients to predict the short-term evolution of CD4 cell counts. For each subgroup, it was quantiﬁed to which extent CD8 cell
counts or CD4/CD8 ratios are prognostic factors for disease progression.
In both subgroups, 2500 NAIVE and 8902 cART patients, past CD4 cells are positively (P<0.0001) and past viral load is negatively
(P<0.0001) associated with the outcome. Including additionally past CD8 cell counts improves the ﬁt signiﬁcantly (P<0.0001) and
increases the marginal explained variation 31.7% to 40.7% for the NAIVE and from 44.1% to 50.7% for the cART group. The past
CD4/CD8 ratio (instead of the past CD8 level) is positively associated with the outcome, increasing the explained variation further to
41.8% for NAIVE and 51.9% for cART.
Abbreviations: AIDS = acquired immune deﬁciency syndrome; patient group with AIDS, ART = antiretroviral therapy, BIC =
Bayesian information criterion for model selection, cART= combined antiretroviral therapy; patient group receiving standard combined
antiretroviral therapy, CD4=CD4 lymphocyte cell countsmeasured permL in bloodplasmaby ﬂowcytometry, CD8=CD8 lymphocyte
cell countsmeasuredpermL in bloodplasmaby ﬂowcytometry, HCV= hepatitisC co-infection, HET= heterosexual patient group,HIV-
1 = human immunodeﬁciency virus of subtype 1, IDU = patient group of intravenous drug users, log(CD4/CD8) = logarithmic (log10)
transformed CD4 to CD8 ratio, log-RNA = logarithmic (log10) transformed RNA measurements, M1 =model 1, M2 =model 2, M3 =
model 3, MSM = patient group of men who have sex with men, NAIVE = patient group with an untreated HIV-1 infection, NRTI =
nucleoside reverse-transcriptase inhibitors, RNA = number of RNA copies per mL blood plasma, SHCS = Swiss HIV cohort study.
Keywords: CD4/CD8 ratio, CD8 cell counts, disease progression, linear mixed model, longitudinal data, predicition
1. Introduction suppression of HIV-1 plasma RNA levels below the detectionAn untreated human immunodeﬁciency virus of subtype 1 (HIV-
1) infection is characterized by declining CD4 target cells which is
associated with the viral load level. Over time, viral load levels in
general tend to increase and CD4 levels continue to decline with
subsequent cellular immunodeﬁciency leading to an acquired
immune deﬁciency syndrome (AIDS) and ultimately death.[1,2]
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cell counts.[7–9] However, already in the early times of HIV
research it was suggested to include additional immune-
activation measures such as CD8 lymphocyte cell counts,
CD4/CD8 ratios or CD4 and CD8 percentages.[10–13] A negative
correlation between changes in CD4 and CD8 cell counts during
an intensiﬁcation of the antiretroviral therapywas reported.[14] In
the Swiss HIV cohort study (SHCS), larger changes in CD4 cell
counts were found to be negatively associated with CD8 cell
counts measured at baseline for HIV-1 patients receiving
antiretroviral therapy.[15] For HIV-1-infected treatment naive
patients, CD8 counts increase, whereas CD4 counts decline[16]
but only viral load and CD4 counts and not CD8 cell counts,
were considered to be the most relevant predictors for disease
progression.[17] Time to normalization of the CD4/CD8 ratio,
deﬁned as 2 subsequent measurements with a ratio between 1 and
1.2 was found to be negatively associated with its baseline
value[18,19] but only a minority of HIV-1-infected individuals
under antiretroviral therapy normalize their CD4/CD8
ratio,[18–20] in particular if treatment was started at low CD4
counts.[3,15,21] Low CD4/CD8 ratios were also found to be
associated with increased morbidity and mortality of non-AIDS-
related death causes.[19,22,23]
These studies all hint toward a possibly important role of CD8
cell counts during an HIV infection. However, up to now an
analysis of the time-dependent relationship between changing
CD8 and CD4 lymphocytes based on a cohort study is lacking.
Furthermore, there is a large inter-patient variation in disease
progression, in CD4 recovery under therapy and in CD4/CD8
normalization, depending on a multitude of factors such as viral
and host factors.[24–26] Here, by taking patient-speciﬁc variation
into account, we examined whether past CD8 cell counts contain
additional information to determine future CD4 cell counts and
investigated this effect separately, for treatment naive individuals
and for patients receiving cART.
2. Methods
2.1. Study population
The SHCS,[27] established in 1988, includes HIV-1-infected
persons >18 years, living in Switzerland. The SHCS has been
approved by the ethical committees of all participating
institutions, and written informed consent has been obtained
from all participants (www.shcs.ch). The SHCS schedules regular
follow-up visits every 6 months, whereas the common clinical
follow-up interval is 3 months, at which CD4 and CD8
lymphocyte cell counts and plasma HIV-1 viral load are
measured. The lymphocyte cell counts per mL blood were
measured by ﬂow cytometry. Since the year 2000 all assays used
for HIV-1 RNA detection had a detection limit of 50 copies per
mL or lower. For this study, the RNA detection limit was set at 50
RNA copies/mL of plasma, independent of the applied assays and
all values below this limit, or without detection, were set to 25
copies/mL. Data were extracted from the October 2014 update of
the SHCS database. Observations prior to the year 2000 were
excluded in order to guarantee comparable assay technology
used to measure plasma RNA load and that an established cART
was available to all patients. We extracted from the database
280,554 lymphocyte cell counts and 325,984 RNA measure-
ments obtained from 11,899 patients.
The study population was divided into 2 subgroups, 1 covers
all observations obtained from patients with an untreated HIV-1
infection (NAIVE), observed as long as they did not start cART.2The second group includes observations from patients receiving
available standard cART (cART). Accordingly the same patient
may be included in both groups, which is the case for 1797
patients or 71.9% of the NAIVE study population.
The following exclusion criteria were applied in the order
illustrated in Fig. 1: Lymphocytes and RNA are not always
measured at the same time, so we matched results of the 2
laboratory analyses if the time difference was <8 days and the
date of the RNA analysis was kept. Observations that were
excluded because no corresponding lymphocyte or RNA
measurement within an 8 days interval was available were
assumed to be missing at random. If a patient quit or interrupted
cART therapy, all follow-up observations were omitted,
independent of a likely therapy resumption. A therapy interrup-
tion is assumed to have an impact on future CD4 cell counts.
Therefore, observations are only included up to the therapy
interruption and censored afterwards. As it was shown that
hepatitis C co-infection (HCV) inﬂuences CD4 cell counts, all
patients with indetermined HCV status were excluded.[28] A
missing HCV test is assumed to be missing at random.Moreover,
all observations with a follow-up time between 2 subsequent
measurements of >12 months were excluded, as the information
of past lymphocyte cell counts and past RNA measurements for
future CD4 counts was assumed to diminish over time. If a
patient met all of the above inclusion criteria he additionally had
to have at least 3 measurements of CD4 and CD8 cell counts as
well as RNA blood viral load, observed at 3 different occasions.
2.2. Statistical methods and analysis
The hypothesis that past CD4/CD8 ratios predict current CD4
cell counts was examined by linear mixed regression models for
longitudinal data[29] for each patient subgroup. The outcome in
each model is the square root transformed CD4 cell count[4,30]
observed at the current follow-up visit. We estimated for both
patient groups 3 models for which we included different
combinations of suitably transformed CD4 and CD8 cell counts,
observed at the preceding follow-up visit, as predictors. In this
way, the inﬂuence of CD4 and CD8 lymphocytes, which are
lagged by 1 follow-up visit, on the outcome is examined. The lag
between 2 subsequent follow-up visits corresponds on average to
a time period of 3 months. From here on predictors are called
lagged if, relative to the observed CD4 cell count outcome, they
were observed at the preceding follow-up visits. In the ﬁrst model
formulation (M1), we included the lagged square root trans-
formed CD4 cell counts and the lagged log10 transformed RNA
measurement as predictors, both observed at the preceding of
2 subsequent follow-up visits. In the second model (M2), we
added the lagged square root transformed CD8 cell counts as
additional predictor. In the third approach (M3), we replaced the
lagged CD8 cell counts by the natural log transformed, lagged
CD4/CD8 ratio.
In order to assess which of the 3 models is most suitable for
each patient group, we compared the marginal R2,[31,32] which is
the proportion of explained variation by the predictors as
proportion of the overall variation. Additionally the models were
compared by a version of the Bayesian information criterion
(BIC), modiﬁed for linear mixed models.[33] The modiﬁed BIC
penalizes the inclusion of model parameters and lower values
indicate that the corresponding model captures more information
and thus should be preferred.
Time was set to zero at cohort entry for the NAIVE and at
therapy initiation for the cART subgroup. The time scale was
SHCS data (1/2000to 10/2014)
pat: 11’899
CD4, CD8 obs: 280’554
RNA obs.: 325’984
pat: 5’757
obs. (CD4 or RNA): 29’090
pat: 10’582
obs. (CD4 or RNA): 248’758
NAIVE cART
incompletemeasurements(RNA missing)
pat: 5’643 (98%)
RNA missing: 27’529(94.6%)
pat: 10’579(99.97%)
RNA missing: 244’100(98.1%)
pat: 114 (2%)
obs: 1’561 (5.4%)
pat: 3 (0.03%)
obs: 4’658 (1.9%)
therapy interruption
pat: 9’915 (93.67%)
obs: 195’616(78.6%)
pat: 664 (6.3%)
obs: 48’484(19.5%)
indeterminate HCV status
pat: 5,498(95.5%)
obs: 27’031(92.9%) pat: 9,599(90.67%)obs: 191’996(77.1%)
pat: 145 (2.5%)
obs: 498 (1.7%)
pat: 316 (3%)
obs: 3’620 (1.5%)
time difference > 12 months
obs: 26’221(90.1%) obs: 189’912(76.3%)
obs: 810 (2.8%) obs: 2’084 (0.8%)
lessthan 3 observations
included NAIVE
pat: 2’500 (43.4%)
obs: 22’405(77%)
included cART
pat: 8’902 (84.07%)
obs: 188’898(75.9%)
pat: 2’998 (52.1%)
obs: 3’816 (13.1%) pat: 697 (6.6%)obs: 1’014 (0.4%)
Figure 1. SHCS data and study population with number of observations (obs.) and number of patients (pat.). Percentages (%) are based on the initial NAIVE or
cART data given on the second level in the diagram. cART = combined antiretroviral therapy; patient group receiving standard combined antiretroviral therapy,
NAIVE = patient group with an untreated HIV-1 infection, SHCS = Swiss HIV cohort study.
Sauter et al. Medicine (2016) 95:42 www.md-journal.comstandardized to 3 month intervals, as this corresponds to the
common clinical follow-up period in the SHCS. For the cART
group, time since therapy start was square root transformed,[34]
as this allowed us to capture the sharp increase in CD4 cell counts
after therapy initiation.[35] We also included AIDS (yes, no) and
age, which are time-dependent, the transmission group (trans-
mission) and the status of a hepatitis C co-infection (HCV), both
observed at baseline, as predictors in all models. The probable
HIV transmission[36] is a categorical predictor with 6 groups: men
who have sexwithmen (MSM),male and female intravenous drug
users (IDU-male, IDU-female), heterosexual males and females
(HET-male, HET-female), and a group for which the transmission
path is not further speciﬁed (other). The HCV status has 3
categories: HCV negative, patients with inactive and patients with
replicating (active) HCV. For the cART patient group, we
additionally included the time period prior to cART during which
an individualwas receivingmonoordual regimenswithnucleoside
reverse-transcriptase inhibitors (NRTI).
In order to address patient-speciﬁc heterogeneity at baseline we
included a random intercept in each model and heterogeneity
between patients in the CD4 cell time course is taken into account
by a random slope, which allows for patient-speciﬁc deviations
from the average time course.[4] The random effect structure is the
same for both subgroups and all 3 model speciﬁcations. An
analysis of the model residuals did not provide evidence for
any longitudinal structure or other dependency. All statistical
analyses and data preparation were done in R version 3.3.0
(2016–05–03). All linear mixed models were ﬁtted with the
software package NLME[37] version 3.1–119.33. Results
3.1. Patient characteristics
According to the above inclusion criteria 2500 patients were
eligible in the NAIVE subgroup with 22,405 observations,
whereas 8902 patients were included in the cART subgroup with
188,898 observations (see Fig. 1). The patient characteristics for
both subgroups are shown in Table 1. The upper part in Table 1
shows the patient characteristics for predictors observed at
baseline and the lower part for time-dependent, longitudinal
predictors based on all included observations.
Patients in the NAIVE, compared to the cART subgroup, had
lower CD4 cell counts (NAIVE 457, cART 497), higher CD8 cell
counts (NAIVE 952, cART 796), a lower CD4/CD8 ratio (NAIVE
0.48, cART0.62), andhigher log-transformedRNAlevels (NAIVE
4.13, cART 1.40). The cART group had more follow-up visits per
patient (NAIVE 7, cART 17), as usually most of the patients start
cART rather quickly and continuously stay under therapy for the
remaining observation time, thus patients are also older at baseline
in the treated group (NAIVE 36, cART 39). The proportion of
patients having AIDS was higher in the cART group (NAIVE
4.9%, cART 24.1%). All other characteristics (follow-up time,
transmission, HCV) were similar for both subgroups.
3.2. Model comparison and predictive value of CD8
lymphocytes
The ﬁrst 2 columns in Table 2 give the marginal R2 for the
3 models and for each patient group. For the NAIVE subgroup,
2Table 1
Patient characteristics for baseline (upper part) and longitudinal (lower part) characteristics of the study population for both subgroups.
Baseline characteristics NAIVE (n=2500) cART (n=8902)
CD4 at baseline 491 (376, 670) 367 (231, 539)
CD8 at baseline 904 (654, 1265) 846 (601, 1185)
CD4/CD8 at baseline 0.55 (0.38, 0.8) 0.41 (0.25, 0.67)
log (RNA) at baseline 4.23 (3.58, 4.8) 1.95 (1.40, 3.11)
AIDS at baseline 46 (1.8%) 1843 (20.7%)
Age at baseline 36 (30, 42) 39 (33, 46)
Transmission
MSM 1181 (47.2%) 3723 (41.8%)
IDU-male 208 (8.3%) 841 (9.4%)
IDU-female 94 (3.8%) 423 (4.8%)
HET-male 415 (16.6%) 1602 (18.0%)
HET-female 506 (20.2%) 1892 (21.3%)
other 96 (3.8%) 421 (4.7%)
HCV
HCV negative 2001 (80.0%) 7056 (79.3%)
HCV inactive 109 (4.4%) 367 (4.1%)
HCV active 390 (15.6%) 1479 (16.6%)
Longitudinal characteristics NAIVE (n=22405) cART (n=188898)
CD4 457 (346, 609) 497 (338, 688)
CD8 952 (694, 1300) 796 (573, 1096)
CD4/CD8 0.48 (0.34, 0.69) 0.62 (0.40, 0.92)
log (RNA) 4.13 (3.50, 4.66) 1.4 (1.40, 1.40)
Follow-up visits per patient 7 (4, 12) 17 (9, 31)
Follow-up time (months) 3.5 (3.0, 5.6) 3.3 (2.8, 5.3)
Data are patient numbers (with %) for discrete and median (with the ﬁrst and third quartile) for continuous predictors. Lymphocyte cell counts and ratio are untransformed, the RNA is log10-transformed.
AIDS = acquired immune deﬁciency syndrome; patient group with AIDS, cART = combined antiretroviral therapy; patient group receiving standard combined antiretroviral therapy, CD4 = CD4 lymphocyte cell
counts measured per mL in blood plasma by ﬂow cytometry, CD8 = CD8 lymphocyte cell counts measured per mL in blood plasma by ﬂow cytometry, HCV = hepatitis C co-infection, HET = heterosexual patient
group, IDU = patient group of intravenous drug users, MSM = patient group of men who have sex with men, NAIVE = patient group with an untreated HIV-1 infection, RNA = number of RNA copies per mL blood
plasma.
Sauter et al. Medicine (2016) 95:42 Medicinethe marginal R increases from 31.7% for M1, to 40.7% for M2
after inclusion of the lagged CD8 cell counts. For cART the
increase is from 44.1% to 50.7%. Including the lagged CD4/CD8
ratio instead of the lagged CD8 cell counts, increases the R2
measure even more to 41.8% for the NAIVE and to 51.9% for
the cART group. The modiﬁed BIC for the 3 models and each
patient group is shown in the last 2 columns of Table 2. The
modiﬁed BIC is decreasing from the model M1 to M3 for both
patient groups. Thus, consistent with the marginal R2, also the
information criterion prefers the model which includes the CD4/
CD8 ratio over the other 2 models.
Figure 2 illustrates the relationship between the lagged
lymphocyte predictors, observed at the ﬁrst follow-up visit and
the outcome, observed at the second of 2 subsequent follow-up
visits. Figure 2 depicts the relationship for the population mean
in the NAIVE (top) and cART (bottom) group. Square rootTable 2
Marginal R2 and modiﬁed BIC for both patient subgroups and 3 mod
Marginal R2
NAIVE
M1: CD4 + RNA 31.7%
M2: CD4 + CD8 + RNA 40.7%
M3: CD4 + CD4/CD8 + RNA 41.8%
All models additionally include an intercept and were adjusted for AIDS, age, transmission, HCV and for ti
Table 3).
BIC = Bayesian information criterion for model selection, cART = combined antiretroviral therapy; patient g
permL in blood plasma by ﬂow cytometry, CD8= CD8 lymphocyte cell counts measured permL in blood pla
copies per mL blood plasma.
4transformed lymphocyte cell counts were back transformed to
absolute cell count values and the log-transformation of the CD4/
CD8 ratio was also reversed. The lower and upper limits for the
predictors in Fig. 2 were set to the 2.5% and 97.5% quantiles of
all observation (0.13–1.8 for the lagged CD4/CD8 ratio and
114–1184 for the lagged CD4). The contour lines of the plots in
the ﬁrst 2 rows indicate the predicted CD4 cell count at the next
follow-up visit, for a given combination of lagged CD4/CD8 ratio
and lagged CD4 cell count. All other predictors in model M2 and
M3 were set to a constant value: time since cohort entry for
NAIVE or since therapy start for cART was set to 3 months,
the age to 40 years, we assumed a median viral load equal to
4.1 (corresponding to 13,380 copies per mL blood) for NAIVE
and a suppressed RNA level for cART (equal to a viral load of
1.4 or 25 copies per mL blood), which occurs for 76.4% of
the observations in this group. The categorical predictors,els including different lagged longitudinal predictors.
Modiﬁed BIC
cART NAIVE cART
44.1% 95,594 865,332
50.7% 95,060 862,400
51.9% 94,962 861,192
me since cohort entry for NAIVE and time since therapy start plus NRTI at baseline for cART (see also
roup receiving standard combined antiretroviral therapy, CD4 = CD4 lymphocyte cell counts measured
sma by ﬂow cytometry, NAIVE= patient group with an untreated HIV-1 infection, RNA= number of RNA
Figure 2. Relation between lagged CD4/CD8 ratio predictor (abscissa), lagged CD4 cell counts predictor (ordinate), and the predicted CD4 cell count outcome
(contour lines) for the population mean in NAIVE (top) and cART (bottom) subgroups in model M2 (left) and M3 (middle) and the empirical distribution of the data
(right) for which the contour lines indicate the location of 80%, 50%, and 20% of the data. cART = combined antiretroviral therapy; patient group receiving standard
combined antiretroviral therapy, NAIVE = patient group with an untreated HIV-1 infection.
Sauter et al. Medicine (2016) 95:42 www.md-journal.comtransmission and HCV, were set to the reference category and
NRTI duration was set to zero.
Figure 2 demonstrates that for model M2 and M3 the
relationship between the lymphocyte predictors and the outcome
is similar for untreated and cART patients. However, the 2
models give considerably different predictions. The plots for
cART and NAIVE based on model M2 (left column) show
converging contour lines in the upper left corner. This leads to
almost vertical contour lines forModelM2, if the CD4/CD8 ratio
is below 0.25, implying a CD8 count which is 4 times larger than
the CD4 cell count. The vertical contour lines mean that in this
range the CD4 lymphocyte level has, according to Model M2, no
more impact on the prediction of CD4 at the next follow-up visit.
Model M3 in contrast, which instead of the CD8 cell counts
includes the CD4/CD8 ratio as predictor, does not have this
feature of quickly converging contour lines (middle column). In
model M3 the level of CD4 lymphocytes is still an important
predictor, even if the CD4/CD8 ratio is <0.25.
The right column in Fig. 2 shows the empirical bivariate
distribution of CD4 cell counts and the CD4/CD8 ratio for
NAIVE and cART patients. The contour lines indicate where
70%, 50% and 10% of the observations are located. For the
NAIVE subgroup 8.3% and for cART 9.7% of the observed data
are below a CD4/CD8 ratio equal to 0.25. The empirical
distribution in Fig. 2 underpins the fact, that the differences
between model M2 and M3 are relevant, as there is a substantial5proportion of observations situated in the bottom left corner,
where the models differ most.3.3. Estimates of regression coefﬁcients
The upper part in Table 3 shows the regression coefﬁcients
together with a 95% conﬁdence interval (CI) for the intercept and
the longitudinal predictors, based on model M3 only which
according to the criteria in Table 2 and Fig. 2 is the preferred
model. The intercept represents the population mean of the
square root transformed CD4 cell counts at baseline (18.02
NAIVE, 15.56 cART). The regression coefﬁcient for time reﬂects
the population mean course of the outcome since cohort entry for
the NAIVE (-0.10) and since therapy start for cART (0.34). These
estimates are in agreement with the established ﬁnding that for
untreated HIV infected patients the CD4 count declines, whereas
an antiretroviral therapy causes an increase. The lagged square
root CD4 cell count, observed at the preceding follow-up visit,
is positively associated with the outcome and has a similar
coefﬁcient for both subgroups (0.36 NAIVE and 0.39 cART).
The negative coefﬁcient for the plasma viral load (–0.46 NAIVE
and –0.27 cART) is in line with the acknowledged decline of CD4
cell counts for higher viral loads. The lagged log-transformed
CD4/CD8 ratio is positively associated with the outcome for both
subgroups (1.79 NAIVE and 1.65 cART). As the CD4/CD8 ratio
is log-transformed, this implies a positive effect if CD4 exceeds
Table 3
Coefﬁcient estimates with 95% conﬁdence intervals (CI) and P-values for model M3 and for both patient subgroups (NAIVE and cART).
NAIVE cART
Coefﬁcient 95% CI P Coefﬁcient 95% CI P
Intercept 18.02 17.43 to 18.61 <0.0001 15.56 15.32 to 15.80 <0.0001
Time 0.10 0.11 to 0.10 <0.0001 <0.0001
Square root time <0.0001 0.34 0.32 to 0.36 <0.0001
Square root CD4 0.36 0.35 to 0.38 <0.0001 0.39 0.39 to 0.40 <0.0001
log RNA 0.46 0.53 to 0.40 <0.0001 0.27 0.29 to 0.25 <0.0001
log CD4/CD8 1.79 1.66 to 1.93 <0.0001 1.65 1.60 to 1.70 <0.0001
AIDS at follow-up visit 0.88 1.28 to 0.48 <0.0001 1.01 1.12 to 0.90 <0.0001
Age at follow-up visit 0.01 0.02 to 0.00 0.0018 0.03 0.03 to 0.02 <0.0001
NRTI at baseline 0.02 0.02 to 0.01 0.00013
Transmission 0.01 <0.0001
MSM (reference) 0.00 0.00
IDU-male 0.14 0.61 to 0.32 1.13 1.39 to 0.88
IDU-female 0.12 0.71 to 0.46 0.75 1.05 to 0.44
HET-male 0.32 0.60 to 0.05 0.64 0.79 to 0.49
HET-female 0.4 0.66 to 0.15 0.47 0.61 to 0.32
Other 0.04 0.55 to 0.46 0.34 0.60 to 0.08
HCV 0.47 <0.0001
Negative (reference) 0.00 0.00
Inactive 0.08 0.59 to 0.44 0.04 0.26 to 0.34
Active 0.13 0.49 to 0.23 0.44 0.64 to 0.23
Upper part shows longitudinal predictors and the lower part time constant predictors for AIDS and age at follow-up visit, NRTI at baseline, transmission, and HCV.
AIDS = acquired immune deﬁciency syndrome; patient group with AIDS, cART = combined antiretroviral therapy; patient group receiving standard combined antiretroviral therapy, CD4 = CD4 lymphocyte cell
counts measured per mL in blood plasma by ﬂow cytometry, CD8 = CD8 lymphocyte cell counts measured per mL in blood plasma by ﬂow cytometry, HCV = hepatitis C co-infection, HET = heterosexual patient
group, IDU = patient group of intravenous drug users, MSM = patient group of men who have sex with men, NAIVE = patient group with an untreated HIV-1 infection, NRTI = nucleoside reverse-transcriptase
inhibitors, RNA = number of RNA copies per mL blood plasma.
Sauter et al. Medicine (2016) 95:42 Medicinethe CD8 cell count, but a negative effect if the ratio is below 1. A
patient with an imbalanced immune system, for whom the CD4 is
below the CD8 cell count, has a lower prediction for the CD4
cells at the next follow-up visit, compared to a patient with equal
CD4 count but with a higher CD4/CD8 ratio.
The regression coefﬁcients for the remaining predictors are
shown in the lower part of Table 3. In contrast to the predictors in
the upper part, these predictors are not time dependent and have
an effect on the predicted CD4 cell count level only. However,
they do not imply differences in the decline or relapse of the
outcome, as they do not include any interactions with time-
dependent longitudinal predictors reported in the upper part of
Table 3. If a patient had AIDS at the time of observation, the CD4
cell count will be lower. Also the patient’s age and the duration of
NRTI prior to cART have a negative level effect on the outcome.
The estimates for the transmission group provides evidence that
the heterosexual transmission categories (HET-male, HET-
female) are different from the reference category (MSM) in the
NAIVE group as the upper bound of the 95% CI is negative. For
the cART group, the 95% CI’s imply that, compared to the
reference category (MSM), all other transmission categories have
a lower CD4 cell count level. For the HCV predictor in the
NAIVE group, there is no evidence for a difference between the 3
categories. However, in the cART group, the corresponding P-
value is small, implying that at least 1 HCV category has a
different CD4 level compared to the HCV negative reference
category, which probably concerns the active HCV category. The
Supplementary Material provides results for model M1 and M2,
as well as additional information.4. Discussion
Based on a large dataset from the Swiss HIV cohort study we
have shown that CD8 cell counts contain crucial predictive6information for the HIV disease progression in drug naive
patients and as well for the CD4 cell count recovery in patients
receiving cART. Both lymphocyte cell subtypes, CD4 and CD8,
as well as the RNA viral load, have been identiﬁed as important
prognostic factors for the CD4 cell count over the next months.
We could show that the model which includes the lagged levels of
CD4 and CD8 as 2 separate predictors was inferior compared to
an approachwhich included the lagged CD4/CD8 ratio instead of
the CD8 level. These ﬁndings persisted, also if we applied
alternative transformations to the lagged lymphocyte predictors,
such as the log instead of the square root transformation. The
CD4/CD8 ratio can be interpreted as a measure for the imbalance
of the patient’s immune system which captures essential
information, additional to the cell count levels of both
lymphocyte subtypes. The CD8 cell count is a marker for
immune activation, which has been found to be an important
factor for disease progression.[38,39]
The relationship between the lagged CD4 cell count predictor,
the lagged CD4/CD8 ratio predictor and the CD4 cell count at the
next follow-up visit were found to be surprisingly similar for
untreated patients and patients under a cART. This was
illustrated by the response surface for the CD4 cell counts in
Fig. 2 and the comparable estimates between NAIVE and cART
for the lymphocyte predictors shown in Table 3.
Furthermore, we could quantify the relative importance of the
2 lymphocyte subtypes and the viral load as prognostic factors. It
was previously found that the viral load only explains a low
proportion (below 10%) of the variation for changes in CD4 cell
counts over 1 year.[6] Such a statement crucially depends on the
outcome and time period for which the prediction is made. We
found that even for NAIVE patients lagged CD8 cell counts are
more important than lagged viral loads in explaining the
variation in future CD4 cell counts. If the lagged RNA predictor
is omitted then the marginal R2 reduces from 31.7% to 27.2% in
Sauter et al. Medicine (2016) 95:42 www.md-journal.comthe approach which includes lagged CD4 as predictor. For the
cART group the marginal R2 is even increasing for the same
model formulation, if the viral load predictor is omitted. This
reﬂects the fact that the association between CD4 cell counts and
viral load is fundamentally different for treatment naive and
patients under therapy. The improved marginal R2 and also the
difference in the regression coefﬁcients of the lagged RNA for the
NAIVE and cART group, supports the argument that although
the viral load is a relevant predictor for future CD4 cell counts, it
explains perhaps only a small proportion of the observed
variation. As the plasma RNA load is often suppressed below the
assay detection limit under cART we also examined the possible
inﬂuence of recurrent detectable plasma RNA viral loads
(“blips”), but no evidence for an additional effect was found.
By choosing a linear mixed model for the longitudinal SHCS
data we could incorporate patient speciﬁc variation for the CD4
cell count at baseline and for its patient-speciﬁc time course. The
applied model simpliﬁed the observation pattern, ignoring
interval censored data and assumed regular follow-up times,
although in the SHCS data there is notable variation for the time
between 2 follow-up visits (see Supplementary Material, http://
links.lww.com/MD/B352). Of course, causal pathways between
the quantities of interest, CD4, CD8 and RNA, are inherently
difﬁcult to assess and not possible to estimate without a minimal
set of assumptions. Nevertheless, we have derived a statistical
model, which allowed us to address the clinically important
question of how the patient’s immune systemwill evolve given the
current state. It would be of interest to examine the sensitivity of
the results with respect to the underlying assumptions. For
example, an alternative analysis would incorporate the underly-
ing rather than the observed lymphocyte and viral load
measurements as predictors.[40] These aspects may constitute
different sources of a potential bias. As mentioned above the
simpliﬁcation of the temporal dependencies, the ignorance of a
measurement error for laboratory analyses but also the
characteristics of the sampling process, for example, sampling
from different centers and regions, may implicitly introduce a bias
in the analysis of this cohort study. To address these aspects,
more investigations would be required and would result in more
complex statistical models, which was beyond the scope of the
presented analysis.
With this statistical analysis of a large HIV cohort, we could
conﬁrm the ﬁndings by other studies, which attributed an
important role to CD8 cells for describing the HIV-1 disease
progression. We were able to show that the CD4/CD8 ratio is an
important time-dependent prognostic factor, for treatment naive
and cART-treated patients. The SHCS data could be used for
further investigations concerning the role of CD8 during an
HIV-1 infection, which could reveal more details about the
connections betweenHIV-1 disease progression and variation for
the time needed to normalize the CD4/CD8 ratio. Elaborating
such associations in more detail, also for interactions of other risk
factors,[41,42] would support the understanding of the mecha-
nisms leading to the high variation in different individual immune
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